<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Precancerous lesions of the prostate: Pathology and clinical implications
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Precancerous lesions of the prostate: Pathology and clinical implications
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Precancerous lesions of the prostate: Pathology and clinical implications
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ximing J Yang, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            W Robert Lee, MD, MS, MEd
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome P Richie, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 30, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The study of precancerous lesions of the prostate is important for understanding prostatic carcinogenesis and for developing potential chemopreventive measures for prostate cancer.
        </p>
        <p>
         Four major pathologic entities will be discussed in this topic review: prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH, also termed adenosis), atrophic lesions, and atypical small acinar proliferation (ASAP). High-grade PIN is the most likely precursor of the majority of prostatic adenocarcinomas. In contrast, AAH and atrophic lesions are possible, although uncertain, precancerous lesions. ASAP is not a true biologic entity but is a diagnostic term in pathology when a lesion suspicious for but not diagnostic of carcinoma is identified. The pathologic characteristics, prevalence, relationship to prostate cancer, and clinical significance of these lesions are discussed in this topic, with a particular emphasis on PIN.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PROSTATIC INTRAEPITHELIAL NEOPLASIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prostatic intraepithelial neoplasia (PIN), first described in 1969 [
         <a href="#rid1">
          1
         </a>
         ], is a neoplastic proliferation of prostatic epithelial cells that is confined to preexisting prostatic ducts or acini (glands). PIN was further characterized and initially termed intraductal dysplasia in 1986 [
         <a href="#rid2">
          2
         </a>
         ]; the currently used term "prostatic intraepithelial neoplasia" was introduced in 1987 and endorsed by consensus at a 1989 conference [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histologic characteristics of PIN have been well described [
         <a href="#rid5">
          5,6
         </a>
         ]. The neoplastic prostatic epithelial cells are within prostatic ducts or acini, which are typically large and branched, with a convoluted inner contour similar to benign glands  (
         <a class="graphic graphic_picture graphicRef58330" href="/z/d/graphic/58330.html" rel="external">
          picture 1
         </a>
         ). Epithelial cell proliferation produces a layer of crowded, pseudostratified, neoplastic cells with cytologic atypia, characterized by nuclear irregularity, nucleomegaly, hyperchromasia, and prominent nucleoli  (
         <a class="graphic graphic_picture graphicRef58330" href="/z/d/graphic/58330.html" rel="external">
          picture 1
         </a>
         ). These findings are similar to those of invasive prostate cancer. (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy"
         </a>
         .)
        </p>
        <p>
         In contrast with adenocarcinoma, the architecture is normal and the PIN glands characteristically contain basal cells around their periphery, seen as a thin and occasionally discontinuous layer on hematoxylin and eosin (H&amp;E) stained sections. Immunohistochemical staining for high molecular weight cytokeratins (34bE12 antibody) easily demonstrates the basal cells  (
         <a class="graphic graphic_picture graphicRef60696" href="/z/d/graphic/60696.html" rel="external">
          picture 2
         </a>
         ). This is an important diagnostic feature because the presence of basal cells can help to differentiate PIN from prostatic adenocarcinoma, in which basal cells are absent [
         <a href="#rid3">
          3,7-10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy"
         </a>
         .)
        </p>
        <p>
         PIN is commonly divided into low-grade (PIN I) and high-grade (PIN II and PIN III) lesions [
         <a href="#rid4">
          4
         </a>
         ]. High-grade PIN differs from low-grade PIN in that cytologic atypia is more apparent, particularly the presence of prominent nucleoli, as observed using a 20x-power lens (200-fold magnification). Several histologic patterns of high-grade PIN have been described: tufting, micropapillary, flat, and cribriform [
         <a href="#rid11">
          11
         </a>
         ]. Other uncommon patterns (ie, mucinous, signet ring cell, and foamy gland) have also been reported [
         <a href="#rid12">
          12,13
         </a>
         ]. The clinical significance of these different patterns is largely unknown, although cribriform PIN and other unusual patterns are almost exclusively seen in patients with invasive cancer, raising the possibility that they may represent intraductal spread of cancer cells [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         PIN is a histologic finding, and its diagnosis can be made only by microscopic examination of prostate tissue (core needle biopsy, transurethral resection [TURP], radical prostatectomy specimens). Digital examination, transrectal ultrasonography, or other imaging studies are not useful for detecting PIN. Furthermore, fine needle aspiration (FNA), which is a popular method for diagnosis of prostate cancer in some countries, cannot distinguish PIN from cancer based on cytologic features alone. (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy"
         </a>
         .)
        </p>
        <p>
         No other clinical or laboratory tests are useful in detecting PIN. Although newer studies using DNA microarray analysis and transgenic mouse models are promising [
         <a href="#rid15">
          15,16
         </a>
         ], no gene or protein that is specific for PIN has been identified to date. The genetic changes that accompany PIN are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6926.html" rel="external">
          "Molecular biology of prostate cancer"
         </a>
         .)
        </p>
        <p>
         While some reports suggesting that PIN might result in an elevation of serum total prostate-specific antigen (PSA) [
         <a href="#rid17">
          17,18
         </a>
         ] or higher values of free serum PSA than prostate cancer [
         <a href="#rid18">
          18,19
         </a>
         ], no correlation between the presence of PIN and either total or free serum PSA has been found by others [
         <a href="#rid19">
          19-23
         </a>
         ]. Therefore, if a man with an elevated serum PSA has isolated high-grade PIN on core needle biopsy, a repeat prostate core needle biopsy may be necessary to rule out other conditions causing PSA elevation, particularly prostate cancer. (See
         <a class="medical medical_review" href="/z/d/html/7568.html" rel="external">
          "Measurement of prostate-specific antigen"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Relationship to cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         PIN is often diagnosed in a specimen that is removed as treatment for other prostatic pathology (eg, in TURP specimens for benign prostatic hyperplasia [BPH]). PIN is a noninvasive neoplastic process, which does not form a tumor mass or cause clinical symptoms.
        </p>
        <p>
         Despite its histologic similarity to carcinoma in situ (CIS), a precursor to invasive cancer that arises in other organs (eg, breast), the term CIS should not be used to describe high-grade PIN because of the variability in its natural history and biologic behavior. PIN may evolve into an invasive cancer, a process that may take more than 10 years to develop [
         <a href="#rid24">
          24
         </a>
         ], it may remain unchanged, or it may even regress. Because PIN is not considered a malignant process and is not symptomatic, aggressive treatment (eg, surgery or radiation) is not warranted.
        </p>
        <p>
         The relationship between PIN and invasive cancer was first elucidated in 1986 [
         <a href="#rid2">
          2,25
         </a>
         ]. In a series of prostate glands obtained at autopsy, PIN was more likely to be found in men with prostate cancer than in those without cancer. Later studies have confirmed the strong association between PIN and invasive prostate cancer. The evidence linking PIN and invasive cancer is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Like prostate carcinoma, high-grade PIN tends to be multifocal, occurs in the peripheral zone of the prostate, and is more prevalent in prostates that harbor carcinomas than in those that do not [
         <a href="#rid26">
          26,27
         </a>
         ]. High-grade PIN can be identified in 80 to 90 percent of radical prostatectomy specimens, often in close proximity to coexisting prostatic adenocarcinoma; sometimes, a direct transition from high-grade PIN to invasive adenocarcinoma can be seen [
         <a href="#rid26">
          26,28-30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In autopsy series, the prevalence of high-grade PIN (7, 12, 36, 38, 45, and 48 percent in the third, fourth, fifth, sixth, seventh, and eighth decades in one series) closely follow the prevalence rates of prostate cancer (4, 9, 14, 24, 32, and 33 percent, respectively) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histologic, biochemical, and molecular similarities have been identified between PIN and prostatic adenocarcinoma [
         <a href="#rid32">
          32-35
         </a>
         ]. Most prostate cancer markers can also be detected in high-grade PIN, although to a lower extent and lower frequency. For example, increased alpha-methylacyl-CoA racemase (AMACR) can be detected in nearly one-half of high-grade PIN cases [
         <a href="#rid36">
          36
         </a>
         ]. The rearrangement of ERG, another prostate cancer marker, can be detected by immunostaining or fluorescence in situ hybridization (FISH) in a small subset of high-grade PIN, ranging from 7 to 20 percent of high-grade PIN, although its positive rate is much higher in prostatic adenocarcinoma (40 to 50 percent) [
         <a href="#rid37">
          37,38
         </a>
         ]. Therefore, these similarities could make the distinction between these two conditions sometimes difficult, even using molecular testing. (See
         <a class="medical medical_review" href="/z/d/html/6926.html" rel="external">
          "Molecular biology of prostate cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The precursor status of PIN has been shown in a transgenic mouse model [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because prostate cancer is the most common visceral malignancy in men, the prevalence of PIN, the major premalignant lesion of the prostate, is also high. However, PIN can only be diagnosed microscopically; as a result, its prevalence in the general population may be underreported.
        </p>
        <p>
         The incidence of PIN varies in different reports, which may be related to the population of men under study, types of specimens, or the diagnostic criteria that are applied. Based upon pathologic examination of prostate glands in autopsy series [
         <a href="#rid2">
          2,24,26,28
         </a>
         ] and from cystoprostatectomy specimens from men who have undergone surgery for bladder cancer [
         <a href="#rid20">
          20,40,41
         </a>
         ], the prevalence of isolated PIN is 40 to 50 percent in men without prostate cancer. Furthermore, both the rate and volume of PIN increase with age [
         <a href="#rid24">
          24,31
         </a>
         ].
        </p>
        <p>
         In contrast, incidence rates, as determined by prostate core needle biopsies in men participating in PSA screening studies, range from 0.7 to 20 percent, while among those undergoing TURP, the incidence varies from 3 to 33 percent [
         <a href="#rid42">
          42-47
         </a>
         ]. The reasons for this disparity appear related to sampling issues. Prostate tissues from TURP specimens are usually sampled from the transition zone  (
         <a class="graphic graphic_diagnosticimage graphicRef50598" href="/z/d/graphic/50598.html" rel="external">
          image 1
         </a>
         ) where PIN is known to be less prevalent.
        </p>
        <p>
         The frequency of concurrent or subsequent diagnosis of invasive cancer may also be higher when more than one biopsy specimen contains high-grade PIN [
         <a href="#rid48">
          48,49
         </a>
         ]. The relationship between the number of involved tissue cores and eventual diagnosis of invasive prostate cancer was illustrated in one series of 245 men with isolated PIN who underwent subsequent biopsies [
         <a href="#rid48">
          48
         </a>
         ]. The only independent histologic predictor of the risk of later invasive cancer was the number of cores involved with PIN: 30, 40, and 75 percent with involvement of one to two, three, or more than three cores. However, these data were obtained when routine six core (sextant) prostate biopsies were the norm. In a more recent series that used an extended biopsy scheme, the number of cores involved with PIN did not reliably predict the risk of finding invasive prostate cancer on rebiopsy [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8097.html" rel="external">
          "Prostate biopsy", section on 'Systematic biopsy'
         </a>
         .)
        </p>
        <p>
         Detection rates of PIN on core needle biopsy specimens also vary based upon the diverse diagnostic standards that are applied by different pathologists and the extent of the biopsy. When samples from 87,713 men in 15 different studies were analyzed using strict diagnostic criteria, the average prevalence of high-grade PIN was 4.26 percent [
         <a href="#rid42">
          42
         </a>
         ], which closely resembles the prevalence of PIN found in our practice.
        </p>
        <p>
         More and more institutions have adopted extended biopsy schema for prostate core needle biopsies. Compared with the traditional sextant biopsy, these schema recommend 10 to 12 tissue cores be obtained during each prostate biopsy session. As a result, detection rate of high-grade PIN on core needle biopsy may increase simply because more tissue cores are obtained [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8097.html" rel="external">
          "Prostate biopsy", section on 'Systematic biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Clinical significance
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          High-grade PIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Men with isolated high-grade PIN on initial core biopsy are thought to have a higher risk of prostate cancer on a subsequent biopsy as compared with those without high-grade PIN. However, this remains a controversial area, and the magnitude of risk is uncertain. In early studies, the risk of finding cancer on rebiopsy ranged from 51 to 100 percent; however, cancer detection rates on repeat biopsy have declined since 1990 and range from 13 to 27 percent in more recent large series  (
         <a class="graphic graphic_table graphicRef76469" href="/z/d/graphic/76469.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid48">
          48,52-58
         </a>
         ].
        </p>
        <p>
         Perhaps the major reason for the declining rate of cancer detection on repeat biopsies for high-grade PIN is that current extended prostate biopsy schema include a higher number of cores (12 cores) than the previously standard sextant of six-biopsy scheme [
         <a href="#rid59">
          59
         </a>
         ]. This leads to the detection of more prostate cancers on the initial biopsies and reduces the predictive value of finding high-grade PIN on core needle biopsy for detecting cancer in rebiopsy.
        </p>
        <p>
         The relationship between the number of cores on initial biopsy, the number of cores on rebiopsy, and the risk of finding cancer in the rebiopsy specimen was illustrated in a series of 791 men with high-grade PIN on initial biopsy who underwent rebiopsy within one year of the diagnosis [
         <a href="#rid57">
          57
         </a>
         ]. Cancer detection rates on rebiopsy varied based upon the biopsy schema; they were highest in men who underwent initial sextant biopsy and who then underwent an extended number of cores for rebiopsy  (
         <a class="graphic graphic_table graphicRef54876" href="/z/d/graphic/54876.html" rel="external">
          table 2
         </a>
         ). The authors concluded that for patients diagnosed with high-grade PIN on extended initial core sampling, a repeat biopsy within the first year was unnecessary in the absence of other clinical indicators of cancer. Others concur [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p>
         Extended biopsy will detect more prostate cancer than sextant biopsy. This is one of the reasons that the predictive value of high-grade PIN is decreasing since many cancer cases have been detected on the initial extended biopsy. Nevertheless, more studies are necessary in order to rationally adjust the rebiopsy strategy in men who are found to have high-grade PIN after undergoing extended core biopsy. Whether such men require rebiopsy is still under investigation. The most important aspect is close clinical follow-up with serum PSA measurement. If there are clinical signs suspicious for prostate cancer, these patients should be rebiopsied.
        </p>
        <p>
         Two factors that may be particularly important in predicting the development of prostate cancer in the setting of high-grade PIN are elevated serum PSA and the presence of adjacent atypical small glands (acini) that are suspicious, but not diagnostic, for prostate cancer (termed atypical small acinar proliferation [ASAP]). (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy", section on 'Cases with diagnostic uncertainty'
         </a>
         .)
        </p>
        <p>
         As noted above, elevated serum PSA concentrations cannot be attributed solely to the presence of high-grade PIN; rebiopsy in such men is particularly important to rule out the presence of prostate cancer. If histologic evaluation reveals the presence of high-grade PIN with adjacent ASAP suspicious for cancer, the risk of documenting cancer on repeat biopsy is 50 percent or more compared with patients with high-grade PIN alone [
         <a href="#rid42">
          42,55,61,62
         </a>
         ].
        </p>
        <p>
         Concomitant high-grade PIN has been associated with good prognosis factors and a favorable oncologic outcome after radical prostatectomy in prostate cancer [
         <a href="#rid63">
          63
         </a>
         ]. However, the reported incidence of high-grade PIN in radical prostatectomy specimens was 54 percent, which is significantly lower than our experience of more than 95 percent of radical prostatectomy cases with prostatic adenocarcinoma. Therefore, it is possible that under-sampling and under-reporting of high-grade PIN in prostatectomy specimens account for this observation. However, high-grade, high-volume prostate cancers are more destructive, which may destroy the major portion of benign prostatic tissue and the tissue harboring high-grade PIN.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Low-grade PIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low-grade PIN has no clinical significance, and men with low-grade PIN do not require a repeat biopsy unless other clinical indicators are present. In fact, it is unnecessary to even include low-grade PIN in the pathologic diagnosis because its presence is not an indication for more aggressive follow-up or treatment.
        </p>
        <p>
         In contrast with high-grade PIN, the presence of low-grade PIN is distinctly different. Histologically, low-grade PIN is characterized by abnormally proliferating secretory cells within acini or ducts, but these cells lack significant cytological atypia. (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Management of high-grade PIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of high-grade PIN on a prostate biopsy is not an indication for aggressive treatment, but instead, the need for close monitoring and possibly for repeat biopsy because of its association with invasive prostate cancer. (See
         <a class="local">
          'Clinical significance'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Rebiopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal rebiopsy strategy is unclear [
         <a href="#rid64">
          64
         </a>
         ]. Although rebiopsy should focus on the original site of PIN, cancer detection rates increase with sampling of adjacent sites and the contralateral lobe in the standard sextant locations. Others recommend the addition of transition zone sampling [
         <a href="#rid55">
          55
         </a>
         ]. Given the decreased predictive value of high-grade PIN in patients with 12 or more core biopsies, rebiopsy is generally not recommended. However, patients with persistently rising serum PSA levels or reasons for clinical suspicion should undergo rebiopsy [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         The management of men with no evidence of invasive prostate cancer on repeat biopsy after an initial biopsy showing isolated high-grade PIN is unclear. Some investigators have found a slightly higher risk of subsequent cancer (24 percent) if high-grade PIN is documented as compared with a totally benign repeat biopsy [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         On the other hand, a 24 percent rate of finding invasive cancer is not insignificant and may be considered high enough that it indicates the need for rebiopsy. One study found that the number of foci of high-grade PIN may be associated with risk of finding prostate cancer in repeat biopsy, which led to a recommendation that an earlier repeat biopsy be carried out in men with more than one core involved by high-grade PIN [
         <a href="#rid66">
          66
         </a>
         ]. Other studies have found that a saturation biopsy scheme increases cancer detection in men with high-grade PIN [
         <a href="#rid67">
          67
         </a>
         ]. Although these biopsy methods and recommendations have not been widely accepted, they can be considered as options. The ideal timing and frequency for rebiopsy following the diagnosis of high-grade PIN remain unclear. Additional studies are needed to address this question.
        </p>
        <p class="headingAnchor" id="H1745086">
         <span class="h3">
          Atypical small acinar proliferation
         </span>
         <span class="headingEndMark">
          —
         </span>
         ASAP is not a biologic entity or a premalignant lesion but a diagnostic term used by some pathologists and understood by clinical colleagues. ASAP is a condition when a pathologist finds a small focus of atypical glands (typically two to three glands, sometimes a few more) suspicious for adenocarcinoma, but there is not sufficient histologic evidence to make a definitive diagnosis of prostatic adenocarcinoma [
         <a href="#rid68">
          68
         </a>
         ]. The diagnosis of ASAP is typically made on a core needle biopsy, occasionally on a TURP specimen, but it is not found in prostatectomy specimens. (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy", section on 'Cases with diagnostic uncertainty'
         </a>
         .)
        </p>
        <p>
         There is a 40 to 50 percent risk of prostate adenocarcinoma with repeat biopsies in a man with ASAP. Generally speaking, the recommendation for ASAP is rebiopsy, if clinically indicated.
        </p>
        <p>
         Although some pathologists may not use the term ASAP, the high risk for prostate cancer and the need for a repeat biopsy in men with a suspicious prostate diagnosis have to be communicated to clinical colleagues. The suspicious area of the prostate may be sampled more extensively but not exclusively; other areas of the prostate with benign diagnosis should also be sampled in a repeat biopsy.
        </p>
        <p>
         The most important issue is that high-grade PIN is totally different from atypical foci suspicious for cancer on prostate core needle biopsy, which carries a much higher risk (40 to 50 percent) of finding cancer at the time of rebiopsy. As a result, men with atypical foci suspicious for adenocarcinoma should be rebiopsied within three to six months, while rebiopsy within one year for men with high-grade PIN alone could be considered optional. (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy", section on 'Cases with diagnostic uncertainty'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Specific treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment that is designed for men with invasive prostate cancer (ie, radical prostatectomy, radiation therapy, androgen ablation) is
         <strong>
          not
         </strong>
         suitable for those with PIN. Although theoretically such treatments could reduce the incidence of PIN and potentially prevent prostate cancer, no medication has been shown to prevent the development of prostate cancer from high-grade PIN.
        </p>
        <p>
         Because of the known influence of neoadjuvant hormone therapy in reducing the incidence of PIN [
         <a href="#rid69">
          69-71
         </a>
         ], it has been suggested that
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         , an oral agent with no impact on serum testosterone levels, may be a useful agent for treating high-grade PIN. The Prostate Cancer Prevention Trial (PCPT) randomly assigned 18,882 men to finasteride (5 mg daily) or placebo, and followed men for seven years with annual digital rectal examination and PSA [
         <a href="#rid72">
          72
         </a>
         ]. The number of men evaluable for high-grade PIN in the finasteride and placebo groups was 4568 and 4866, respectively. Men were evaluable for high-grade PIN if they had a diagnosis of high-grade PIN or invasive cancer on an interim or end of study biopsy, or if they had a completely negative biopsy at the end of study endpoint (seven years). When men diagnosed with high-grade PIN alone or high-grade PIN concurrently with invasive prostate cancer were examined jointly, those receiving finasteride had a significant 21 percent lower risk of high-grade PIN (9.2 versus 11.7 percent, hazard ratio [HR] 0.79, p = 0.001). (See
         <a class="medical medical_review" href="/z/d/html/6949.html" rel="external">
          "Chemoprevention strategies in prostate cancer"
         </a>
         .)
        </p>
        <p>
         Based upon our experience, blockade of 5-alpha reductase (5-AR) with
         <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">
          finasteride
         </a>
         does not cause obvious change in the morphology of prostate cancer on histologic evaluation [
         <a href="#rid73">
          73
         </a>
         ]. Unlike other forms of androgen deprivation therapy, the effects of finasteride on morphology of high-grade PIN and Gleason score are unknown [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         In randomized trials, 5-AR inhibitors have been shown to significantly decrease the incidence of prostate cancer. However, no trials have demonstrated an impact of prostate cancer mortality, and the possibility that these agents increase the incidence of high-grade lesions cannot be excluded. (See
         <a class="medical medical_review" href="/z/d/html/6949.html" rel="external">
          "Chemoprevention strategies in prostate cancer", section on 'Finasteride: PCPT'
         </a>
         .)
        </p>
        <p>
         Another clinical trial, using
         <a class="drug drug_general" data-topicid="10164" href="/z/d/drug information/10164.html" rel="external">
          toremifene
         </a>
         , an estrogen agonist/antagonist, was conducted in men with high-grade PIN, but toremifene also failed to prevent the development of prostate cancer [
         <a href="#rid75">
          75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          ATYPICAL ADENOMATOUS HYPERPLASIA (ADENOSIS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast with high-grade prostatic intraepithelial neoplasia (PIN), the evidence for premalignant potential of atypical adenomatous hyperplasia (AAH) is inconclusive. AAH was first described in 1941 [
         <a href="#rid76">
          76
         </a>
         ] and further characterized as a distinct entity in 1965 [
         <a href="#rid77">
          77
         </a>
         ]. Another synonym, "adenosis," was introduced in 1986 [
         <a href="#rid78">
          78
         </a>
         ]. Although the term AAH was advocated in a consensus meeting [
         <a href="#rid79">
          79
         </a>
         ], some experts consider the term "atypical" inappropriate for this condition, leading to confusion with prostate cancer or a lesion that is suspicious for prostate cancer (eg, atypical small acinar proliferation [ASAP]). (See
         <a class="local">
          'Clinical significance'
         </a>
         above.)
        </p>
        <p>
         AAH is defined as a well-circumscribed lobule of closely packed crowded small glands (acini) [
         <a href="#rid80">
          80
         </a>
         ]. Similar to low-grade prostatic adenocarcinoma, AAH typically lacks significant cytologic atypia despite its abnormal architecture  (
         <a class="graphic graphic_picture graphicRef56973" href="/z/d/graphic/56973.html" rel="external">
          picture 3
         </a>
         ). However, in contrast with invasive cancer, the presence of basal cells, although patchy in distribution, is characteristic of AAH and demonstrable by immunostaining for high molecular weight cytokeratins (34bE12)  (
         <a class="graphic graphic_picture graphicRef56973" href="/z/d/graphic/56973.html" rel="external">
          picture 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy"
         </a>
         .)
        </p>
        <p>
         The reported prevalence of AAH is between 1.6 to 19.6 percent of transurethral resection (TURP) specimens and from 5 to 23 percent of radical prostatectomy specimens [
         <a href="#rid81">
          81-83
         </a>
         ]. This wide range is likely due to variable diagnostic criteria employed by different pathologists. In our practice, AAH is found in less than 5 percent of TURP or radical prostatectomy specimens when relatively strict diagnostic criteria are applied. In addition to its low prevalence, AAH is often present without coexisting adenocarcinoma, and direct transition from AAH to invasive cancer has been seen only rarely.
        </p>
        <p>
         There is controversy as to whether AAH is a premalignant lesion. Because most AAH is located in the transition zone  (
         <a class="graphic graphic_diagnosticimage graphicRef50598" href="/z/d/graphic/50598.html" rel="external">
          image 1
         </a>
         ), where low-grade prostatic adenocarcinoma is often situated, it has been hypothesized that AAH is a precursor for low-grade prostate cancer [
         <a href="#rid84">
          84
         </a>
         ]. Furthermore, the histologic and cytological features are intermediate between benign prostatic hyperplasia (BPH) and low-grade carcinoma [
         <a href="#rid85">
          85
         </a>
         ]. Because of its low prevalence, AAH is unlikely to be responsible for the majority of prostatic adenocarcinoma. In fact, AAH is often present without coexisting adenocarcinoma. Direct transition from AAH to cancer has been seen only rarely. There is no convincing clinical follow-up information available to link AAH and prostate cancer.
        </p>
        <p>
         Evidence from clinical, biochemical, and molecular analyses of AAH have generated inconclusive results to substantiate the notion that AAH is a premalignant lesion [
         <a href="#rid86">
          86-89
         </a>
         ]. However, our study demonstrated that 17.5 percent of AAH overexpressed alpha-methylacyl-CoA racemase (AMACR), which is considered a molecular marker for prostate cancer [
         <a href="#rid87">
          87
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy", section on 'Immunohistochemistry'
         </a>
         ). This finding strongly suggested that at least a small subset of AAH might be a precursor for low-grade adenocarcinoma in the prostatic transition zone.
        </p>
        <p>
         If some cases of AAH do have malignant potential, it is likely to represent the minority of cases. In general, the majority of AAH can be considered benign, and immediate rebiopsy is not indicated in men with isolated AAH unless other clinical indicators or pathologic warnings are present. It is possible that AAH will be eventually divided histologically and biochemically into benign conditions (the majority), which do not require rebiopsy, and atypical lesions (the minority), which warrant rebiopsy and close follow-up. Further studies are needed to clarify the role of AAH in the pathogenesis of low-grade prostate cancer and to determine its clinical significance. A comparison between prostatic adenocarcinoma, high-grade PIN, and AAH is listed in the table  (
         <a class="graphic graphic_table graphicRef54876" href="/z/d/graphic/54876.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H277039867">
         <span class="h1">
          INTRADUCTAL CARCINOMA OF THE PROSTATE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intraductal carcinoma of the prostate (IDCP) is a newly defined entity that has been described in detail [
         <a href="#rid90">
          90,91
         </a>
         ]. IDCP is important because it may be confused with high-grade prostatic intraepithelial neoplasia (PIN). This entity is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy", section on 'Intraductal carcinoma of the prostate'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          ATROPHY AND ATROPHIC LESIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The relationship between atrophy and atrophic lesions of the prostate and prostate adenocarcinoma is even less clear. Atrophy is histologically recognized by the presence of small acini and ducts with a reduced amount of cytoplasm. In contrast with its name and appearance, atrophy is not a degenerative process, but rather, a proliferative condition [
         <a href="#rid92">
          92
         </a>
         ]. Atrophic prostatic lesions include a spectrum of conditions, namely typical atrophy [
         <a href="#rid93">
          93
         </a>
         ], postatrophic hyperplasia [
         <a href="#rid94">
          94
         </a>
         ], partial atrophy [
         <a href="#rid95">
          95
         </a>
         ], and proliferative inflammatory atrophy [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
         Atrophic lesions are very common in the peripheral zone of the prostate where most prostate adenocarcinomas develop. Atrophic lesions do not correlate with the size of the prostate. Although finding coexistent atrophy and prostate cancer is not uncommon [
         <a href="#rid97">
          97
         </a>
         ], a causal relationship has not been defined. It has been proposed that proliferative inflammatory atrophy is a precursor of high-grade prostatic intraepithelial neoplasia (PIN) or a precursor of prostate adenocarcinoma because of its frequency in the peripheral zone and proliferative nature, though more studies are necessary to substantiate this claim. It is not clear whether proliferative inflammatory atrophy is just a histologic variant of atrophy similar to postatrophic hyperplasia or a distinct pathologic entity linked to the development of high-grade PIN. Furthermore, the diagnosis of proliferative inflammatory atrophy cannot be established on hematoxylin and eosin (H&amp;E) stained slides alone because immunostaining with a proliferative marker, such as Ki-67, is needed to identify its presence. At present, atrophy and its variants are considered benign conditions, and their presence does not warrant a repeat biopsy if other clinical indications are absent.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prostatic intraepithelial neoplasia (PIN) is a neoplastic proliferation of epithelial cells within the benign preexisting ducts or acini. PIN is histologically divided into low-grade and high-grade lesions. High-grade PIN is considered to be a premalignant lesion and a precursor of the majority of prostate cancer cases. PIN is typically not associated with any clinical symptoms or signs, or associated with an elevation of prostate-specific antigen (PSA). Imaging studies have not shown to be useful in identifying PIN either. Therefore, the only preoperative diagnosis of PIN is obtained from prostate core needle biopsy. (See
         <a class="local">
          'Histology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neoplastic cells in high-grade PIN share many features with invasive prostatic adenocarcinoma based upon their morphologic appearance, and biochemical and molecular genetic characteristics. The key difference is that PIN is noninvasive, similar to carcinoma in situ (CIS), and typically associated with the presence of basal cells. The natural history and latent period for PIN to progress to cancer are unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is a strong association between the presence of high-grade PIN on prostate biopsy and the presence of prostate adenocarcinoma. The optimal strategy for rebiopsy in men with high-grade PIN but without prostate cancer is unclear. Generally, these patients with isolated high-grade PIN need to be followed, at least with serial PSA levels. In contrast, low-grade PIN does not appear to have clinical significance, and rebiopsy is not indicated. (See
         <a class="local">
          'High-grade PIN'
         </a>
         above and
         <a class="local">
          'Low-grade PIN'
         </a>
         above and
         <a class="local">
          'Rebiopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with atypical small acinar proliferation (ASAP) on prostate biopsy should have repeat biopsy, as prostate cancer will be subsequently identified in 40 to 50 percent of cases. (See
         <a class="local">
          'Atypical small acinar proliferation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whether other lesions are precursors of prostate cancer is less certain. Atypical adenomatous hyperplasia (AAH) is characterized by a well-circumscribed lobule of crowded small glands without significant cytologic atypia. Whether AAH is a premalignant lesion is controversial, but it appears to be a benign lesion in most, if not all, cases. Atrophy and atrophic lesions are very common in the prostate and typically are considered benign. Although these lesions can be proliferative in nature, whether there is a relationship between such atrophic lesions and prostatic adenocarcinoma is not conclusive. Therefore, rebiopsy is not indicated for men with benign atrophic lesions of the prostate. (See
         <a class="local">
          'Atypical adenomatous hyperplasia (adenosis)'
         </a>
         above and
         <a class="local">
          'Atrophy and atrophic lesions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4083848682">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges E David Crawford, MD, who contributed to an earlier version of this topic review.
        </p>
        <p>
         We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate gratefully acknowledges Dr. Vogelzang's role as Section Editor on this topic, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           McNeal JE. Origin and development of carcinoma in the prostate. Cancer 1969; 23:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986; 17:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987; 59:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drago JR, Mostofi FK, Lee F. Introductory remarks and workshop summary. Urology 1992; 39:2.
          </a>
         </li>
         <li class="breakAll">
          Bostwick DG, Srigley J. Premalignant lesions. In: Pathology of the prostate, Bostwick DG (Ed), Churchill-Livingston, New York 1990. p.37.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovi J, Mostofi FK, Heshmat MY, Enterline JP. Large acinar atypical hyperplasia and carcinoma of the prostate. Cancer 1988; 61:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 1985; 45:3663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol 1990; 417:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 1999; 23:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG, Amin MB, Dundore P, et al. Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol 1993; 24:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reyes AO, Swanson PE, Carbone JM, Humphrey PA. Unusual histologic types of high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 1997; 21:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman DM, Yang J, Epstein JI. Foamy gland high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 2000; 24:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovi J, Jackson MA, Heshmat MY. Ductal spread in prostatic carcinoma. Cancer 1985; 56:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bull JH, Ellison G, Patel A, et al. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 2001; 84:1512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdulkadir SA, Qu Z, Garabedian E, et al. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 2001; 7:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brawer MK, Lange PH. Prostate-specific antigen and premalignant change: implications for early detection. CA Cancer J Clin 1989; 39:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horninger W, Volgger H, Rogatsch H, et al. Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project. J Urol 2001; 165:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos CG, Carvahal GF, Mager DE, et al. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. J Urol 1999; 162:1587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang, XY, Kim, HL. High grade prostatic intraepithelial neoplasia does not cause significant elevation of prostate specific antigen (abstract). Mod Pathol 2001; 14:99A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ronnett BM, Carmichael MJ, Carter HB, Epstein JI. Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? J Urol 1993; 150:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander EE, Qian J, Wollan PC, et al. Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration. Urology 1996; 47:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morote J, Raventós CX, Encabo G, et al. Effect of high-grade prostatic intraepithelial neoplasia on total and percent free serum prostatic-specific antigen. Eur Urol 2000; 37:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeal JE. Significance of duct-acinar dysplasia in prostatic carcinogenesis. Urology 1989; 34:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qian J, Wollan P, Bostwick DG. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 1997; 28:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004; 17:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI, Cho KR, Quinn BD. Relationship of severe dysplasia to stage A (incidental) adenocarcinoma of the prostate. Cancer 1990; 65:2321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinn BD, Cho KR, Epstein JI. Relationship of severe dysplasia to stage B adenocarcinoma of the prostate. Cancer 1990; 65:2328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin M, Takayama H, Nonomura N, et al. Extent and zonal distribution of prostatic intraepithelial neoplasia in patients with prostatic carcinoma in Japan: analysis of whole-mounted prostatectomy specimens. Prostate 2000; 42:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Chapado M, Olmedilla G, Cabeza M, et al. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate 2003; 54:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996; 29:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeal JE, Alroy J, Leav I, et al. Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. Am J Clin Pathol 1988; 90:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alcaraz A, Barranco MA, Corral JM, et al. High-grade prostate intraepithelial neoplasia shares cytogenetic alterations with invasive prostate cancer. Prostate 2001; 47:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zitzelsberger H, Engert D, Walch A, et al. Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 2001; 84:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu CL, Yang XJ, Tretiakova M, et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 2004; 35:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu H, Shi J, Wilkerson M, et al. Immunohistochemical evaluation of ERG expression in various benign and malignant tissues. Ann Clin Lab Sci 2013; 43:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morais CL, Guedes LB, Hicks J, et al. ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma. Hum Pathol 2016; 55:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci U S A 1998; 95:15382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbas F, Hochberg D, Civantos F, Soloway M. Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Eur Urol 1996; 30:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Troncoso P, Babaian RJ, Ro JY, et al. Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens. Urology 1989; 34:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsikafi NF, Brendler CB, Gerber GS, Yang XJ. High-grade prostatic intraepithelial neoplasia with adjacent atypia is associated with a higher incidence of cancer on subsequent needle biopsy than high-grade prostatic intraepithelial neoplasia alone. Urology 2001; 57:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudin PB, Sesterhenn IA, Wojno KJ, et al. Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens. Urology 1997; 49:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacelli A, Bostwick DG. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens. Urology 1997; 50:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoedemaeker RF, Kranse R, Rietbergen JB, et al. Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer 1999; 85:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67:2949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skjørten FJ, Berner A, Harvei S, et al. Prostatic intraepithelial neoplasia in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate. Cancer 1997; 79:1172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001; 25:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prange W, Erbersdobler A, Hammerer P, et al. Significance of high-grade prostatic intraepithelial neoplasia in needle biopsy specimens. Urology 2001; 57:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naya Y, Ayala AG, Tamboli P, Babaian RJ. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy? Urology 2004; 63:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humilier M, Yang XJ. Increased detection of high grade prostatic intraepithelial neoplasia (PIN) by using additional lateral prostate needle biopsy (abstract). Modern Pathol 2002; 15:165a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vis AN, Hoedemaeker RF, Roobol M, et al. The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer. Cancer 2001; 92:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamoi K, Troncoso P, Babaian RJ. Strategy for repeat biopsy in patients with high grade prostatic intraepithelial neoplasia. J Urol 2000; 163:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefkowitz GK, Taneja SS, Brown J, et al. Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2002; 168:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borboroglu PG, Sur RL, Roberts JL, Amling CL. Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol 2001; 166:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson D, Bostwick DG, Qian J, et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 1995; 154:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herawi M, Kahane H, Cavallo C, Epstein JI. Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. J Urol 2006; 175:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godoy G, Huang GJ, Patel T, Taneja SS. Long-term follow-up of men with isolated high-grade prostatic intra-epithelial neoplasia followed by serial delayed interval biopsy. Urology 2011; 77:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Khalek M, El-Baz M, Ibrahiem el-H. Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model. BJU Int 2004; 94:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronz JD, Shaikh AA, Epstein JI. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. Hum Pathol 2001; 32:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scattoni V, Roscigno M, Freschi M, et al. Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies. Urology 2005; 66:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingels A, Ploussard G, Allory Y, et al. Concomitant high-grade prostatic intraepithelial neoplasia is associated with good prognosis factors and oncologic outcome after radical prostatectomy. Urol Int 2014; 92:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer JE, Rovner ES, Coleman BG, et al. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol 1996; 155:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefkowitz GK, Sidhu GS, Torre P, et al. Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? Urology 2001; 58:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrimen JL, Jones G, Walker D, et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol 2009; 182:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee MC, Moussa AS, Zaytoun O, et al. Using a saturation biopsy scheme increases cancer detection during repeat biopsy in men with high-grade prostatic intra-epithelial neoplasia. Urology 2011; 78:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med 2000; 124:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balaji KC, Rabbani F, Tsai H, et al. Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance. J Urol 1999; 162:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferguson J, Zincke H, Ellison E, et al. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 1994; 44:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vailancourt L, Ttu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 1996; 20:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson IM, Lucia MS, Redman MW, et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 2007; 178:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang XJ, Lecksell K, Short K, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 53:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG, Qian J. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 2001; 58:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taneja SS. Re: prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Urol 2013; 190:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baron E, Angrist A. Incidence of occult adenocarcinoma of the prostate after 50 years of age. Arch Pathol 1941; 32:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeal JE. Morphogenesis of prostatic carcinoma. Cancer 1965; 18:1659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brawn PN. Adenosis of the prostate: a dysplastic lesion that can be confused with prostate adenocarcinoma. Cancer 1982; 49:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG, Algaba F, Amin MB, et al. Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate. Am J Surg Pathol 1994; 18:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG, Srigley J, Grignon D, et al. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol 1993; 24:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in transurethral resection specimens. Am J Surg Pathol 1994; 18:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qian J, Bostwick DG. The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Pathol Res Pract 1995; 191:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in needle biopsy specimens. Am J Surg Pathol 1995; 19:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grignon DJ, Sakr WA. Atypical adenomatous hyperplasia of the prostate: a critical review. Eur Urol 1996; 30:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helpap B, Bonkhoff H, Cockett A, et al. Relationship between atypical adenomatous hyperplasia (AAH), prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma. Pathologica 1997; 89:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng L, Shan A, Cheville JC, et al. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res 1998; 58:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002; 26:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Häussler O, Epstein JI, Amin MB, et al. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. Hum Pathol 1999; 30:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doll JA, Zhu X, Furman J, et al. Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis). Am J Pathol 1999; 155:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol 2006; 19:1528.
          </a>
         </li>
         <li class="breakAll">
          Epstein JI, Oxley J, Ro JY, et al. Intraductal carcinoma. In: WHO classification of tumours of the urinary system and male genital organs, 4th ed, Moch H, Humphrey PA, Ulbright TM, Reuter VE (Eds), World Health Organization, Lyon 2016. p.164.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998; 22:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardner WA Jr, Culberson DE. Atrophy and proliferation in the young adult prostate. J Urol 1987; 137:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheville JC, Bostwick DG. Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma. Am J Surg Pathol 1995; 19:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oppenheimer JR, Wills ML, Epstein JI. Partial atrophy in prostate needle cores: another diagnostic pitfall for the surgical pathologist. Am J Surg Pathol 1998; 22:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000; 56:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amin MB, Tamboli P, Varma M, Srigley JR. Postatrophic hyperplasia of the prostate gland: a detailed analysis of its morphology in needle biopsy specimens. Am J Surg Pathol 1999; 23:925.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6925 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5763258" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Origin and development of carcinoma in the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3943853" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Intraductal dysplasia: a premalignant lesion of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2433020" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prostatic intra-epithelial neoplasia and early invasion in prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Introductory remarks and workshop summary
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Introductory remarks and workshop summary
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3338023" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Large acinar atypical hyperplasia and carcinoma of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2410099" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Keratin immunoreactivity in the benign and neoplastic human prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1696762" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2469333" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9989840" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8454275" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Architectural patterns of high-grade prostatic intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9331295" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Unusual histologic types of high-grade prostatic intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10632499" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Foamy gland high-grade prostatic intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4027893" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Ductal spread in prostatic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11384102" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11135623" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Impaired prostate tumorigenesis in Egr1-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2482117" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prostate-specific antigen and premalignant change: implications for early detection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11257656" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10524873" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : High grade prostatic intraepithelial neoplasia does not cause significant elevation of prostate specific antigen (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7686984" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8650867" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10765077" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effect of high-grade prostatic intraepithelial neoplasia on total and percent free serum prostatic-specific antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8326560" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2603288" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Significance of duct-acinar dysplasia in prostatic carcinogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9023393" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14739906" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : High-grade prostatic intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2346916" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Relationship of severe dysplasia to stage A (incidental) adenocarcinoma of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2346917" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Relationship of severe dysplasia to stage B adenocarcinoma of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10617864" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Extent and zonal distribution of prostatic intraepithelial neoplasia in patients with prostatic carcinoma in Japan: analysis of whole-mounted prostatectomy specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12518329" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8700801" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Molecular biology of prostatic intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2455443" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11304727" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : High-grade prostate intraepithelial neoplasia shares cytogenetic alterations with invasive prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11161378" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chromosomal changes during development and progression of prostate adenocarcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15297968" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23462600" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Immunohistochemical evaluation of ERG expression in various benign and malignant tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27189342" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9860977" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8931964" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2603286" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11182340" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : High-grade prostatic intraepithelial neoplasia with adjacent atypia is associated with a higher incidence of cancer on subsequent needle biopsy than high-grade prostatic intraepithelial neoplasia alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9111625" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9301697" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9921986" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1710531" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9070495" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prostatic intraepithelial neoplasia in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11474294" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11248625" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Significance of high-grade prostatic intraepithelial neoplasia in needle biopsy specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15028446" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Increased detection of high grade prostatic intraepithelial neoplasia (PIN) by using additional lateral prostate needle biopsy (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11505396" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10687984" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Strategy for repeat biopsy in patients with high grade prostatic intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12352407" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11490235" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7544835" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16406886" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131029" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Long-term follow-up of men with isolated high-grade prostatic intra-epithelial neoplasia followed by serial delayed interval biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16469560" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15329106" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11331955" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16286121" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23919964" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Concomitant high-grade prostatic intraepithelial neoplasia is associated with good prognosis factors and oncologic outcome after radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7490841" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11744476" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19524976" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22054382" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Using a saturation biopsy scheme increases cancer detection during repeat biopsy in men with high-grade prostatic intra-epithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10629139" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10458359" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8042266" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8540613" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17499284" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Finasteride decreases the risk of prostatic intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10197843" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502458" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23845334" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Re: prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Incidence of occult adenocarcinoma of the prostate after 50 years of age
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4158629" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Morphogenesis of prostatic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7055791" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Adenosis of the prostate: a dysplastic lesion that can be confused with prostate adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7522413" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8375853" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7520673" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Adenosis of the prostate. Histologic features in transurethral resection specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8606866" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7793471" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Adenosis of the prostate. Histologic features in needle biopsy specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8875202" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Atypical adenomatous hyperplasia of the prostate: a critical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9270265" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Relationship between atypical adenomatous hyperplasia (AAH), prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9458077" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Atypical adenomatous hyperplasia of the prostate: a premalignant lesion?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12131160" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10492043" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10487854" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16980940" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16980940" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9737239" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Histology and cellular kinetics of prostatic atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2432282" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Atrophy and proliferation in the young adult prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7544958" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9537471" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Partial atrophy in prostate needle cores: another diagnostic pitfall for the surgical pathologist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11068311" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10435562" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Postatrophic hyperplasia of the prostate gland: a detailed analysis of its morphology in needle biopsy specimens.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
